This document provides an overview of common lesions of the oral cavity and salivary glands, including inflammatory, preneoplastic, and neoplastic conditions. Key topics discussed include oral leukoplakia, squamous cell carcinoma, ameloblastoma, pleomorphic adenoma, Warthin's tumor, mucoepidermoid carcinoma, and adenoid cystic carcinoma. The document describes the etiology, pathogenesis, morphology, and clinical manifestations of these various oral and salivary gland lesions.
Includes most common tumors of oral cavity including scc,bcc, melanoma, ameloblastoma, odontoma, fibromas, pindborg tumors etc.
Presented by Dr. Binaya Subedi
Salivary gland tumours are a relatively rare and morphologically diverse group of lesions. So here are slides containing information about salivary gland tumours with images.
Includes most common tumors of oral cavity including scc,bcc, melanoma, ameloblastoma, odontoma, fibromas, pindborg tumors etc.
Presented by Dr. Binaya Subedi
Salivary gland tumours are a relatively rare and morphologically diverse group of lesions. So here are slides containing information about salivary gland tumours with images.
Cutaneous manifestations of internal malignancy and paraneoplastic syndromes gamal sultan
cutaneous manifestations are extremely valuable marker because they may well be the presenting manifestation of an underlying neoplasm.
Increased clinician awareness could prove beneficial for the patient by promoting earlier screening and diagnosis, as well as increased intervention measures, thereby significantly affecting the chances of survival and/or improving the quality of life of the patient
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
1. Dr Neha Mahajan
MBBS,MD Pathology
PDCC Hematopathology
Associate Professor
Lesions of Oral cavity and
salivary glands
2. Understand the common disorders of the
upper airway and upper digestive tract (i.e.,
head and neck) in the usual context of:
DEGENERATIVE,
INFLAMMATORY,
and
NEOPLASTIC
…deviations of normal anatomy and histology
22. ORAL LEUCOPLAKIA
Def: Leukoplakia(white plaque) may be clinically
defined as a white plaque or patch on oral mucosa
not exceeding 5 mm in diameter, which cannot be
rubbed off nor can be classified into any diagnosable
disease.
CAUSES OF WHITE LESIONS :
Benign: Fordyce`s granules,Hairy
tongue,Leukoedema,Lupus erythematosus,white
sponge nevus.
Premalignant:Leukoplakia,Oral lichen planus
Malignant: Squamous cell carcinoma
23. INCIDENCE:
Males>Females
Lesions-variable size & appearances
Site: Cheek mucosa,angles of mouth,alveolar
mucosa,angles of mouth, alveolar mucosa,
tongue, lip, hard & soft palate
4 to 6% cases progress to carcinoma
Speckled and nodular forms-malignant
transformation.
ALL WHITE PATCHES BE
BIOPSIED
24.
25. ETIOLOGY:
Strong association with
tobacco(smoking,paan,zarda,gutkha)
Smokers keratosis/Stomatitis nicotina.
Other factors- chonic friction and local irritation
HAIRY LEUCOPLAKIA- seen in patients of AIDS.
MORPHOLOGY:
Lesions- white,whitish yellow,red velvety >5mm
Circumscribed,slightly elevated,smooth or
wrinkled,speckled,nodular.
MICROSCOPY:
1.Hyperkeratotic
2.Dysplastic
33. ODONTOGENIC
CYSTS/TUMORS
INFLAMMATORY CYSTS (e.g., “Radicular”[peri-apical]
most common inflammatory cyst)
DEVELOPMENTAL CYSTS (DENTIGEROUS most
common developmental cyst and surgical specimen)
MALIGNANT TUMORS of ODONTOGENIC ORIGIN
(AMELOBLASTOMAS) (rare)
34. Ameloblastoma
Most common benign but locally invasive
epithelial odontogenic tumor.
3rd to 5th decade.
Sites:Mandible in molar ramus area and maxilla
Tumor originates from dental epithelium of
enamel or epthelium residues,epithelium lining of
dentigerous cysts.
X ray- multilocular destruction of bone
35. they ma yarise from
rests of dental lamina
a developing enamel organ
the epithelial lining of an odontogenic cyst
the basal cells of the oral mucosa
the epithelial cell rests of Malessez
36. Three different clinicoradiographic situations
1)Conventional solid or multicystic (86%)
2)Unicystic (13%)
3)Peripheral (Extraosseous) (1%)
differing therapeutic considerations and prognosis.
37.
38. Radiographic feature
Multilocular radiolucent lesion, soap bubble / honey
combed
Buccal & lingual cortical expansion
resorption of the roots of teeth
"soap bubble" appearance.
In many cases an unerupted teeth specially 3rd molar is associated with defect
"honeycombed" appearance.
39. Histopathologic Features
I. Follicular
II. plexiform
III. Acanthomatuos
IV. granular cell
V. desmoplastic
VI. basal cell
The follicular and plexiform patterns are the most common
No correlation
between clinical
behavior and these
microscopic
patterns
47. Benign Malignant
Pleomorphic adenoma (50%)
(mixed tumor)
Mucoepidermoid carcinoma
(15%)
Warthin tumor (5% to 10%) Adenocarcinoma (NOS)
(10%)
Oncocytoma (1%) Acinic cell carcinoma (5%)
Other adenomas (5% to 10%) Adenoid cystic carcinoma
(5%)
Basal cell adenoma Malignant mixed tumor (3% to
5%)
Canalicular adenoma Squamous cell carcinoma
(1%)
Ductal papillomas Other carcinomas (2%)
Histologic Classification and Incidence of Benign and Malignant Tumors of
the Salivary Glands
48. PLEOMORPHIC ADENOMA
Most common tumor of major (60 to 75%) and
minor (50%) salivary glands.
Benign tumors that consist of mixture of
ductal(epithelial) &mesenchymal differentiation
Histological diversity-Mixed tumors.
Common in women,3rd to 5th decade.
Painless,slow growing,mobile discrete masses.
Recurrence.
Carcinoma ex pleomorphic adenoma.
49.
50.
51. WARTHIN`S TUMOR
PAPILLARY CYSTADENOMA
LYMPHOMATOSUM.
Benign neoplasm,second most common salivary
gland neoplasm.
RESTRICTED TO PAROTID.
Males> Females, 5th to 7th decade
10% cases are bilateral &multifocal.
GROSS: Round to oval encapsulated masses,2 to
5cm in diameter.Cut section pale gray with cytic &
cleft like spaces filled with seromucionous secretions
MICROSCOPY:These spaces are lined by double
layer of neoplastic cells resting on dense lymphoid
stroma with germinal centres.Inner columnar
epithelium with eosinophilic granular cytoplasm over
52.
53.
54. MUCOEPIDERMOID CARCINOMA
Most common malignant salivary gland
tumor(major & minor glands)
30 to 60 years
Most common example of radiation induced
malignant tumor.
GROSS: Circumscribed, unencapsulated,1 to 4
cm.
MICROSCOPY: Low,Intermediate & high grade
depending upon degree of differentiation & tumor
invasiveness.
4 types of cells: Mucin
producing,squamous,Intermediate & clear cells.
55. Prognosis: Low-grade tumors- invade locally and
recur in about 15% of cases, but only rarely do
they metastasize and so yield a 5-year survival
rate of more than 90%.
High-grade neoplasms and, to a lesser extent,
intermediate-grade tumors are invasive and
difficult to excise and so recur in about 25% to
30% of cases and, in 30% of cases, metastasize
to distant sites.
The 5-year survival rate in patients with these
tumors is only 50%.
56.
57. ADENOID CYSTIC
CARCINOMA
Adenoid cystic carcinoma is a relatively
uncommon tumor.
50% of cases is found in the minor salivary
glands (in particular the palate). Parotid and
submandibular glands,nose, sinuses, and upper
airways and elsewhere.
Morphology: Small, poorly encapsulated,
infiltrative, gray-pink lesions.
Microscopy: Small cells with dark, compact
nuclei and scant cytoplasm. Patterns- tubular,
solid, or cribriform patterns .The spaces between
the tumor cells are often filled with a hyaline
material thought to represent excess basement
membrane.
58.
59. Adenoid cystic carcinomas are relentless and
unpredictable tumors with a tendency to invade
perineural spaces and they are stubbornly
recurrent.
50% or more disseminate widely to distant sites
such as bone, liver, and brain, sometimes
decades after attempted removal.
Thus, although the 5-year survival rate is about
60% to 70%, it drops to about 30% at 10 years
and 15% at 15 years.
Neoplasms arising in the minor
salivary glands have, on average,
a poorer prognosis than those
primary in the parotids.
60. What have we studied???
Lesions of Oral Cavity
Inflammatory (Pyogenic granuloma,Fibroma,Canker
sore,Mucocele,Glossitis
Preneoplastic(Leukoplakia)
Neoplastic(Squamous cell carcinoma)
Lesions of Odontogenic origin
Ameloblastoma
Salivary gland neoplasm.
Benign(Pleomorphic adenoma,Warthins tumor)
Malignant(Mucoepidermoid,Adenoid cystic
carcinoma,Acinic cell carcinoma)